Skip to main content

Table 1 Demographic and clinical data

From: The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old

  no-ATT PI VKA DOAC p value
n 80 41 32 33  
Age 74 (64.5–81) 80 (72–86) 81 (74–85) 82 (75.5–84.5) < 0.0001
Male gender (n/%) 48 (60%) 21 (51.2%) 15 (46.9%) 14 (42.4%) ns
GCS 14 (12–15) 14.5 (12.75–15) 14 (13–15) 14 (14–15) ns
AIS Head 3 (2–4) 3 (3–4) 3 (3–4.75) 3 (2.25–4) ns
ISS 13 (9–17) 14.5 (9–18) 14.5 (9.25–23.75) 10 (9–16) ns
Charlson Comorbidity Index 3 (2–5) 4 (3.5–5) 4 (4–6) 5 (4–6) 0.0006
Number of CCT 3 (2–5) 3 (3–5) 3.5 (2–6) 3 (2–5) ns
ICH progression (n/%) 27 (33.7) 16 (39.0) 19 (59.4) 8 (24.2) 0.023
ICU length of stay 46 (21.25–112.3) 47 (25–108) 70 (29.25–159.5) 49 (22–92) ns
Hospital length of stay 242 (123–407.5) 217 (121–413) 278.5 (109.5–368) 168 (76–345.5) ns
  1. no-ATT no antithrombotic therapy, PI platelet inhibitors, VKA vitamin K antagonists, DOAC direct oral anticoagulants, GCS Glasgow coma scale, AIS abbreviated injury score, ISS injury severity score, CCT cranial computer tomography, ICH intracranial haematoma, ICU intensive care unit, ns not significant
  2. ANOVA and Dunnett’s comparison of all columns vs. control column
  3. Chi square test
  4. Median (interquartile range, 25th–75th)